3 Reasons Celgene Will Bounce Back This Year
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
The market's up-and-down performance in 2014 has taken its toll on the biotech sector, and big biotech Celgene hasn't been immune to the sectorwide slump. Celgene's shares have fallen by double-digit percentages since the year kicked off, even as...
Final Glance: Biotechnology companies
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Here's What This Billion-Dollar Financial Advisor Has Been Buying and Selling
Selena Maranjian, The Motley Fool - Motley Fool - Wed Apr 23, 4:15PM CDT
Every quarter, many money managers have to disclose what they've bought and sold, via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at investment advisory firm Douglass Winthrop Advisors. It's of...
Will Celgene (CELG) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 3:30PM CDT
Celgene Corporation (CELG) is set to report first quarter 2014 results on Apr 24 before market opens.
Why Biogen (BIIB) Stock Is Down Today
at The Street - Wed Apr 23, 12:55PM CDT
Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today
Midday Glance: Biotechnology companies
AP - Wed Apr 23, 12:37PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Strong Q1 Earnings at Gilead on Stellar Sovaldi Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 11:00AM CDT
Gilead beat estimates on the back of strong Sovaldi sales.
First Week Of CELG June 21st Options Trading
at The Street - Wed Apr 23, 10:06AM CDT
Investors in Celgene Corp. saw new options become available this week, for the June 21st expiration.
Early Glance: Biotechnology companies
AP - Wed Apr 23, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene to Rise Like a Phoenix: Opinion
at The Street - Wed Apr 23, 5:21AM CDT
Celgene's share price offers both growth or value investors something to like.
A Drill Can Help Identify Right Time To Sell Leaders
at Investor's Business Daily - Tue Apr 22, 5:11PM CDT
When leading stocks fall, you need to read the situation impartially. However, if you have a position in a top stock from a top group, emotions can cloud judgment. You might sell in fear, or you might hold firm in stubbornness. A drill is the best...
Drug firm exec gets 16 months in inside-trade case
AP - Tue Apr 22, 3:58PM CDT
NEWARK, N.J. (AP) — A former pharmaceutical executive has been sentenced to 15 months in prison for his role in an insider trading scheme.
After Yesterday's Rally of 1.95% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 22, 3:49PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $144.10 to a high of $147.50. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $144.07 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upcoming Earnings Announcements -- Research on Superior Energy Services, Celgene, Penn National Gaming, and PerkinElmer
PR Newswire - Tue Apr 22, 11:32AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Superior Energy Services Inc. (NYSE: SPN), Celgene Corp. (NASDAQ: CELG), Penn National Gaming Inc. (NASDAQ: PENN) and PerkinElmer Inc. (NYSE: PKI). Full earnings notes on SPN, CELG, PENN and PKI can be downloaded upon signing up at:
What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...